Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryJapanJapan
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

Sugammadex sodium

Sugammadex sodium
Contact us for more batch information
Select Batch
Purity:99.44%
Resource Download

Sugammadex sodium

Catalog No. T5326Cas No. 343306-79-6
Sugammadex sodium (Org25969) , a synthetic derivative of γ-cyclodextrin, is a steroid-based neuromuscular blocker reversing agent.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Pack SizePriceAvailabilityQuantity
5 mg$34In Stock
10 mg$54In Stock
25 mg$86In Stock
50 mg$117In Stock
100 mg$163In Stock
200 mg$263In Stock
500 mg$493In Stock
Bulk & Custom
Add to Cart
Questions
View More

Related Compound Libraries of "Sugammadex sodium"

Product Introduction

Bioactivity
Description
Sugammadex sodium (Org25969) , a synthetic derivative of γ-cyclodextrin, is a steroid-based neuromuscular blocker reversing agent.
In vivo
Injection of 100 microg/kg rocuronium resulted in a mean neuromuscular blockade of 93.0%, and profound blockade was achieved by injection of 500 microg/kg. After injection of the high rocuronium dose, the 90% recovery of the train-of-four ratio took 28 min after saline, 26 min after 1 mg/kg sugammadex, and 8 min after 2.5 mg/kg sugammadex. Signs of residual blockade or recurarization were not observed [1]. Treatment with 16 mg/kg and 100 mg/kg sugammadex had a neuroprotective effect in a transient global cerebral I/R rat model. However, 100 mg/kg sugammadex was more neuroprotective in rats [2].
Animal Research
The animals were anesthetized with 80 mg/kg ketamine hydrochloride and 12 mg/kg xylazine administered intraperitoneally. After the rats were anesthetized, the bilateral common carotid arteries were exposed and carefully separated from the carotid sheath and the cervical sympathetic and vagal nerves through a ventral cervical incision. The bilateral common carotid arteries were occluded with nontraumatic aneurysm clips in ischemic rats but were not clamped in sham-operated rats. Complete interruption of the blood flow was confirmed by observing the central artery in the retina with an ophthalmoscope. The body temperature of the rats was maintained at 37.0 ± 0.5°C during this procedure. In this model, 10 minutes of ischemia and 24 hours of reperfusion were induced. After the ischemic period, the rats were treated with sugammadex 16 mg/kg (S 16 group) and sugammadex 100 mg/kg (S 100 group) (intravenous and total volume 1 mL) in the 5th minute of reperfusion. Sugammadex was diluted with normal saline (0.9% NaCl). The same surgical procedure was performed in the I/R group, but the rats were not treated with sugammadex. The neck incision was closed with sutures (3.0 silk), and the animals were allowed to awaken. After 24 hours, the neurological condition of the rats was assessed with a scoring system [2].
AliasOrg25969, Sugammadex (sodium)
Chemical Properties
Molecular Weight2178.01
FormulaC72H104Na8O48S8
Cas No.343306-79-6
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year
Solubility Information
H2O: 34 mg/mL (15.61 mM)
Solution Preparation Table
H2O
1mg5mg10mg50mg
20 mM0.0230 mL0.1148 mL0.2296 mL1.1478 mL
50 mM0.0092 mL0.0459 mL0.0918 mL0.4591 mL
100 mM0.0046 mL0.0230 mL0.0459 mL0.2296 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
%Tween 80
%ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords